Oric Pharmaceuticals director sells 3,500 shares

Q: How many ORIC shares did Richard A. Heyman sell?

Richard A. Heyman sold 3,500 directly held shares, and RAHD Capital, LLC sold 3,200 shares held of record by the LLC. Both sales were reported at $12.9141 per share and were effected under a Rule 10b5-1 trading plan adopted by Heyman and RAHD Capital, LLC.

Q: How many ORIC options did Richard A. Heyman exercise?

On October 1, 2026, Heyman exercised 3,500 options at an exercise price of $1.60 per share, acquiring 3,500 common shares. The options were fully vested and immediately exercisable. The option entry reports 26,700 shares following the exercise.

The sales were effected under a Rule 10b5-1 plan and included 3,200 shares held by RAHD Capital, LLC.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Oric Pharmaceuticals, Inc. director Richard A. Heyman exercised 3,500 options on October 1, 2026, acquiring 3,500 common shares at an exercise price of $1.60 per share. He sold 3,500 directly held shares, and RAHD Capital, LLC sold 3,200 shares held of record by the LLC; Heyman had voting and investment power over the LLC-held shares. Both sales were effected under a Rule 10b5-1 trading plan adopted by Heyman and RAHD Capital, LLC, and were reported at $12.9141 per share, with trade prices ranging from $12.57 to $13.39. The option entry reports 26,700 shares following the exercise.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 4 txns

Insider Heyman Richard A.

Role Director

Sold 6,700 shs ($87K)

Approx. gross sale proceeds $87K

Approx. exercise cost $6K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy) ^F4	3,500	$0.00	$0.00
Exercise	Common Stock	3,500	$1.60	$6K
Sale	Common Stock ^{F1, F2}	3,500	$12.9141	$45K
Sale	Common Stock ^{F1, F2, F3}	3,200	$12.9141	$41K

Holdings After Transaction: Stock Option (right to buy) — 26,700 contracts (Direct); Common Stock — 38,300 shares (Direct); Common Stock — 203,472 shares (Indirect, See footnote)

Footnotes (4)

F1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC.
F2. This transaction was executed in multiple trades at prices ranging from $12.57 to $13.39. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3. The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares.
F4. The shares subject to the option are fully vested and immediately exercisable.

Key Figures

Options exercised: 3,500 options Exercise price: $1.60 per share Directly held shares sold: 3,500 shares +4 more

7 metrics

Options exercised 3,500 options October 1, 2026

Exercise price $1.60 per share Options exercised October 1, 2026

Directly held shares sold 3,500 shares October 1, 2026

Shares sold by RAHD Capital, LLC 3,200 shares Held of record by the LLC; October 1, 2026

Reported sale price $12.9141 per share Sales on October 1, 2026

Sale trade-price range $12.57 to $13.39 per share Sales on October 1, 2026

Shares reported following option exercise 26,700 shares Option entry

Key Terms

Rule 10b5-1 trading plan, fully vested and immediately exercisable, exercise price, voting and investment power

4 terms

Rule 10b5-1 trading plan regulatory

"sales reported were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

fully vested and immediately exercisable technical

"shares subject to the option are fully vested and immediately exercisable"

exercise price financial

"at an exercise price of $1.60"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

voting and investment power regulatory

"has voting and investment power with respect to such shares"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ORIC shares did Richard A. Heyman sell?

Richard A. Heyman sold 3,500 directly held shares, and RAHD Capital, LLC sold 3,200 shares held of record by the LLC. Both sales were reported at $12.9141 per share and were effected under a Rule 10b5-1 trading plan adopted by Heyman and RAHD Capital, LLC.

How many ORIC options did Richard A. Heyman exercise?

On October 1, 2026, Heyman exercised 3,500 options at an exercise price of $1.60 per share, acquiring 3,500 common shares. The options were fully vested and immediately exercisable. The option entry reports 26,700 shares following the exercise.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/02/2026 - 05:51 PM Accepted by SEC EDGAR 10/02/2026 - 05:50 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Heyman Richard A.

(Last)

(First)

(Middle)

C/O ORIC PHARMACEUTICALS, INC.

240 E. GRAND AVE., 2ND FLOOR

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Oric Pharmaceuticals, Inc. [ ORIC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/01/2026		M		3,500	A	$1.6	41,800	D
Common Stock	10/01/2026		S⁽¹⁾		3,500	D	$12.9141⁽²⁾	38,300	D
Common Stock	10/01/2026		S⁽¹⁾		3,200	D	$12.9141⁽²⁾	203,472	I	See footnote⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$1.6	10/01/2026		M			3,500	⁽⁴⁾	02/28/2028	Common Stock	3,500	$0	26,700	D

Explanation of Responses:

1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC.

2. This transaction was executed in multiple trades at prices ranging from $12.57 to $13.39. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares.

4. The shares subject to the option are fully vested and immediately exercisable.

	/s/ Christian Kuhlen, attorney-in-fact	10/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR